Kristen explains why patient support programs (PSPs) need to evolve as products move from launch through growth, maturity, and loss of exclusivity. She outlines how manufacturers can recalibrate the balance of technology, automation, and human support at each stage to improve efficiency while maintaining strong patient and healthcare provider experiences.
To learn more about AssistRx's approach to patient support across the product lifecycle, download the AssistRx lifecycle playbook suite.
Read on for Kristen's insights.
Patient Support Strategy by Lifecycle Stage: Launch, Growth, Maturity, and Loss of Exclusivity
By Kristen Magee, Vice President, Methodology & Enablement, AssistRx
At every stage of the specialty product lifecycle, the role of patient support services shifts. At launch these services support product experience, establish access and build prescribing momentum. Through growth and maturity, they scale efficiently with automation so live support concentrates where it changes outcomes. Approaching loss of exclusivity (LOE), the right program ensures retention against generic or biosimilar entry.
Knowing when and how to recalibrate patient support strategies is what sustains program performance and the patient and healthcare provider (HCP) experiences across the full lifecycle.
Patient Support at Launch: Mitigating Access Friction
At launch, patient support programs (PSPs) have the biggest budgets and the most cross-functional buy-in, but also the greatest uncertainty. Products face both clinical excitement and heavy payer scrutiny simultaneously. This is also where first impressions for HCPs and patients matter most.
Launch is when the balance of manual to automated processes skews most heavily toward human expertise. While e-support services should be ready to handle volume, people handle exceptions—and at launch, exceptions are common. Here, the most advanced programs make human expertise faster and more efficient with AI-powered agent assistance, sentiment analysis and automated quality assurance.
In this phase, payer policy tactics, like prior authorization (PA) criteria, formulary blocks and quantity limits, are some of the most common friction points for HCPs and patients. Prescriber confidence is earned at this stage. Real-time benefit verification and automated PA technology built into established workflows, like AssistRx Advanced Benefit Verification and Advanced Prior Authorization, remove that friction.
During launch, free goods assistance offerings can support patient and HCP access while payer hurdles are resolved. When these programs are administered within a single vendor that leverages automation, coordination and commercial coverage conversion are scalable, reliable and rapid.
Growth and Maturity: Building Efficiencies at Scale
Once the program clears launch – product on formulary, payer policy written, program volume stable – the opportunity shifts to efficiency. At this point, exceptions become less frequent, benefit verification and PA results can be returned in seconds, and payer tactics are predictable enough to design around. Now, it is time to evaluate whether the program crafted at launch meets the new needs of a product at its growth and maturity phases.
A few signals suggest a program has stopped keeping pace: high-touch steps that could be automated but haven't been; slipping service levels, especially during growth; a partner who reports on performance but does not advise any changes to it. The right partner evolves alongside the product, moving manual processes to automation without sacrificing service levels. Further, they proactively recommend those changes to build efficiencies into the program.
Should these signals persist, it may be time to evaluate a program transition to a new partner. Done with the right methodology and proven experience, patients, caregivers and HCPs experience the benefits of an optimized program.
Loss of Exclusivity: Prioritizing Experience at Lower Cost
As products approach LOE, cost efficiency becomes the priority as generic and biosimilar products begin to enter the market. Between 2026 and 2030, about 200 drugs will face this circumstance, making it the industry’s biggest patent cliff to date.
Once these new entrants become available, payers are quick to prefer them over brand names. The deciding factor for many patients and HCPs, in addition to clinical efficacy, is how easy the brand is to access and adhere to. To deliver on experience and efficiency, the program should emphasize seamlessly moving patients through their access journey.
Products at this stage also face significant counter switching, or when a generic or biosimilar is substituted for the prescribed therapy at the pharmacy counter. This reality can be combatted with a select pharmacy network, inclusive of commercial, free drug and consignment pharmacies, to uphold the clinical decision for branded product utilization.
Triggering enrollment directly from the EHR keeps the HCP in their workflow, starts support immediately and puts the patient's first interaction minutes away instead of days. AssistRx’s CoAssist solution works this way, pairing EHR-triggered intake with tech-first, cost-effective digital patient services and a pharmacy network that support patients from therapy initiation through ongoing adherence – all with lower costs and improved data visibility.
The Right Patient Support Program Strategy at Every Lifecycle Stage
At this point, life sciences organizations should be asking:
- Which phase is our product in, and does the support model still match?
- Is our current partner advising on the next change—or waiting to be asked?
- Are our current program capabilities able to evolve throughout the lifecycle?
AssistRx has published its lifecycle playbook suite—three playbooks covering how PSPs support products at launch, mid-lifecycle transition and loss of exclusivity. Download the suite.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Marie Caldwell (mcaldwell@hmpglobal.com).
No comments:
Post a Comment